EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Hypoxia‐inducible factor 2α inhibition in renal cell carcinoma: From von Hippel–Lindau biology to targeted therapeutics

Yu-Wei Chen, Fumika Sano, Rana R McKay iD

Cancer · 15.11.2026 · 132 (22)

DOI: 10.1002/cncr.70682 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 13.11.2026. Verfasst von Yu-Wei Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University of California, San Diego, Moores Cancer Center, San Diego, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Basic Helix-Loop-Helix Proteins, Kidney Neoplasms, Von Hippel-Lindau Tumor Suppressor Protein. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear cell renal cell carcinoma (ccRCC) is characterized by the dysregulation of cellular oxygen sensing resulting from inactivation of the von Hippel–Lindau (VHL) tumor‐suppressor gene. Loss of VHL function leads to constitutive activation of hypoxia‐inducible factor (HIF) signaling, with HIF‐2α emerging as the dominant oncogenic driver of angiogenesis, metabolic reprogramming, tumor growth, and metastasis. The discovery of a druggable cavity within the HIF‐2α PAS‐B domain transformed a previously undruggable transcription factor into a therapeutic target and enabled the development of selective HIF‐2α inhibitors. Belzutifan, the first approved HIF‐2α inhibitor, has demonstrated meaningful clinical activity in VHL disease–associated neoplasms and advanced ccRCC, validating direct inhibition of the VHL–HIF pathway as a therapeutic strategy. More recently, belzutifan in combination with pembrolizumab was approved as adjuvant therapy for patients with resected ccRCC. Separately, the development of next‐generation HIF‐2α inhibitors, HIF‐1β (also known as aryl hydrocarbon receptor nuclear translocator)–targeted degraders, and novel combination strategies, including those incorporating vascular endothelial growth factor–targeted therapies, continues to broaden the therapeutic potential of HIF‐directed treatment. In this review, the authors summarize the biologic basis of the VHL–HIF axis, the development of HIF‐targeted therapies, key clinical data supporting their use in renal cell carcinoma, and future directions for this rapidly evolving therapeutic class.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellBasic Helix-Loop-Helix ProteinsKidney NeoplasmsVon Hippel-Lindau Tumor Suppressor Proteinvon Hippel-Lindau DiseaseHumansEndothelial PAS Domain-Containing Protein 1Molecular Targeted TherapyAnimalsSignal TransductionAntineoplastic Agents

Stichwörter der Autor:innen

belzutifandrug therapymolecular‐targeted therapyrenal cell carcinomavon Hippel–Lindau disease

Substanzen

Basic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1Von Hippel-Lindau Tumor Suppressor ProteinVHL protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Medical Oncology, University of California, San Diego, Moores Cancer Center, San Diego, California, USA.
  • University of California, San Diego School of Medicine, San Diego, California, USA.

ORCID-Profile: Rana R McKay

Zitieren

APA

Chen, Y. W., Sano, F., & McKay, R. R. (2026). Hypoxia‐inducible factor 2α inhibition in renal cell carcinoma: From von Hippel–Lindau biology to targeted therapeutics. Cancer, 132(22). https://doi.org/10.1002/cncr.70682

Vancouver

Chen YW, Sano F, McKay RR. Hypoxia‐inducible factor 2α inhibition in renal cell carcinoma: From von Hippel–Lindau biology to targeted therapeutics. Cancer. 2026;132(22). doi:10.1002/cncr.70682

BibTeX
@article{Chen2026,
  author = {Chen, Yu-Wei and Sano, Fumika and McKay, Rana R},
  title = {Hypoxia‐inducible factor 2α inhibition in renal cell carcinoma: From von Hippel–Lindau biology to targeted therapeutics},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {22},
  doi = {10.1002/cncr.70682}
}
Kostenlos starten →